·Production workshop passed FDA audit with zero defects ·Recommended by multiple authoritative domestic and international guidelines such as NCCN, CSCO, and CACA, and is a Category 1A recommended drug for third-line treatment of metastatic colorectal cancer (mCRC)

*For contraindications and adverse reactions, please see the package insert

·The first generic azacitidine drug in China to complete bioequivalence studies according to the "Draft Guidance on Azacitidine" issued by the US FDA and pass confirmatory clinical trials

*For contraindications and adverse reactions, please see the package insert

·An NK-1 receptor antagonist, administered in combination with other antiemetic drugs, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy ·Recommended by multiple domestic and international guidelines, including NCCN, ASCO, ESMO, and CSCO ·Holds multiple patents for preparation, analysis, and API production equipment

*For contraindications and adverse reactions, please see the package insert

·Passed the national consistency evaluation for the quality and efficacy of generic drugs ·Approved for 3 indications in China: lung cancer, pancreatic carcinoma, and breast cancer ·Selected in the fourth round of national centralized drug procurement ·Recommended by multiple authoritative guidelines such as CSCO and NCCN

*For contraindications and adverse reactions, please see the package insert

·A first-line standard treatment drug for the chronic, accelerated, and blast phases of Ph+ chronic myeloid leukemia (CML), and is also applicable for Ph+ acute lymphoblastic leukemia (ALL) ·Listed as a core therapeutic drug for CML in the "CSCO Guidelines for the Diagnosis and Treatment of Malignant Hematological Diseases" and the "China CML Diagnosis and Treatment Guidelines" ·Convenient oral treatment

*For contraindications and adverse reactions, please see the package insert

·Available in 1.0 mg, 2.5 mg, and 3.5 mg ·Multiple guidelines, including NCCN and ESMO, recommend Bortezomib as a backbone drug for the entire course of multiple myeloma treatment (induction consolidation, high-risk maintenance, relapsed/refractory)

*For contraindications and adverse reactions, please see the package insert

·Used in combination with Trastuzumab for the treatment of HER2-positive early breast cancer and metastatic breast cancer ·Pertuzumab is recommended by multiple authoritative domestic and international guidelines (NCCN, CSCO, CACA, etc.). The dual-target combination therapy with Trastuzumab is the current standard of care for perioperative treatment of HER2-positive early breast cancer and first-line treatment of advanced breast cancer

*For contraindications and adverse reactions, please see the package insert

·An oral small-molecule multi-target receptor tyrosine kinase inhibitor (TKI) ·Inhibits the kinase activity of RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-α, etc., thereby inhibiting tumorigenesis, tumor angiogenesis, tumor metastasis, and tumor immunity ·A systemic therapeutic drug for second-line treatment of hepatic cancer, third-line treatment of colorectal cancer, and third-line treatment of gastrointestinal stromal tumors ·Recommended as the gold standard in NCCN guidelines, guidelines for the diagnosis and treatment of primary hepatic cancer, CSCO guidelines, etc.

*For contraindications and adverse reactions, please see the package insert